Cipla Q1 pre-tax profit jumps 20% to Rs 799 crore on strong revenues

Firm's domestic business did well, up 16% YoY during the quarter when Cipla launched licensed version of Gilead's remdesivir

Mumbai headquartered Cipla posted 20 per cent growth in profit before tax (PBT) for the first quarter of the current financial year to Rs 799 crore, on a 9 per cent year-on-year (YoY) growth in revenues to Rs 4,346 crore. The company’s domestic business did well, registering a 16 per cent YoY jump during the quarter when Cipla launched the licensed version of Gilead’s remdesivir. It also markets another key drug used in Covid treatment, Roche’s tocilizumab. In the chronic therapies, cardiac segment did well for Cipla during the quarter, growing by 10 per cent. The trade generics business clocked